IMMP News and Press, Immutep Limited From 07/30/25

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries Trial-in-Progress poster for TACTI-004 presented at the 2025 Ameri...

SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivota...

SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating...

Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune di...

Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation at a future medical meeting SYDNEY, AUSTRALIA, May 27, 202...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area of high unmet need Data de...

2025-05-08 08:46:59 ET Summary Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, e...

2025-05-05 14:00:34 ET Immutep Surges 28% on Keytruda Combo Trial Result Driving Gains in PRISM Emerging Pharmaceuticals Immutep Limited ( IMMP ) soared 27.54% to lead the PRISM Emerging Pharmaceuticals Index after reporting impressive median overall survival (OS) results ...

2025-05-05 12:31:21 ET Immutep (NASDAQ: IMMP ) shares rose 25% following the announcement of compelling new data from its Phase IIb TACTI-003 trial. The combination of the company's immunotherapy candidate, eftilagimod alfa (efti), and Merck's KEYTRUDA(R) (pembrolizumab) delivered a...

2025-05-05 11:31:09 ET Immutep Limited (NASDAQ: IMMP) is one of today’s top gainers. The company’s shares have moved 34.21% on the day to $2.29. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The ...